Literature DB >> 11793371

Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group.

Giovanni Tallini1, Howard Dorfman, Peter Brys, Paola Dal Cin, Ivo De Wever, Christopher D M Fletcher, Kjell Jonson, Nils Mandahl, Fredrik Mertens, Felix Mitelman, Juan Rosai, Anders Rydholm, Ignace Samson, Raf Sciot, Herman Van den Berghe, Roberta Vanni, Helena Willén.   

Abstract

The evaluation of chondroid lesions requires full integration of clinical, radiographic, and pathological data; tumour typing is often a challenge for the diagnostic pathologist. Although a variety of chromosomal abnormalities have been documented in chondroid lesions, the potential usefulness of cytogenetic analysis remains unclear. This study has critically reviewed and analysed 117 karyotyped samples from 100 patients with cartilaginous and chordoid tumours. Cases were selected based on successful chromosomal analysis and adequacy of clinical, radiographic, and pathological information. To ensure objective evaluation, the cytogenetic results were correlated in a double-blind setting with consensus diagnoses independently determined on each case, after complete review of the histological, radiographic, and clinical findings. Karyotypic aberrations were identified in 41/92 cartilaginous tumours (5/11 osteochondromas, 2/3 chondromyxoid fibromas, 0/4 chondroblastomas, 11/29 chondromas, 0/3 chondroid tumours of undetermined malignant potential, 22/40 chondrosarcomas and 1/2 miscellaneous cartilaginous lesions) and 5/8 chordomas. Complex karyotypic changes were a feature of malignant tumours (chondrosarcoma and chordoma) and of chondrosarcoma among cartilaginous tumours, where they correlated with high tumour grade. Among primary well-differentiated cartilaginous lesions of bone, the finding of an abnormal karyotype was consistently associated with a grade 1 chondrosarcoma diagnosis. Among karyotypically abnormal cartilaginous tumours, loss of distal 8q was associated with osteochondroma, +5 with synovial chondroma/chondromatosis and parosteal or soft tissue chondroma, alterations of chromosome arm 6q with chondromyxoid fibroma, +7 with bone chondrosarcoma, and 17p1 alterations with grade 3 chondrosarcoma. Alterations involving 12q13 characterized synovial chondroma/chondromatosis in the chondroma group and myxoid chondrosarcoma of bone in the chondrosarcoma group. In conclusion, cytogenetic abnormalities in chondroid lesions are common and are not randomly distributed. They are associated with malignancy/tumour grade as well as with specific diagnoses in many cases, and can therefore be of potential value for tumour typing. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 11793371     DOI: 10.1002/path.1023

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

Review 3.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

4.  Heterogeneous and complex rearrangements of chromosome arm 6q in chondromyxoid fibroma: delineation of breakpoints and analysis of candidate target genes.

Authors:  Salvatore Romeo; Ronald A J Duim; Julia A Bridge; Fredrik Mertens; Danielle de Jong; Paola Dal Cin; Pauline M Wijers-Koster; Maria Debiec-Rychter; Raf Sciot; Andrew E Rosenberg; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  Am J Pathol       Date:  2010-08-09       Impact factor: 4.307

5.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

6.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

7.  Spinal chondrosarcoma: a review.

Authors:  Pavlos Katonis; Kalliopi Alpantaki; Konstantinos Michail; Stratos Lianoudakis; Zaharias Christoforakis; George Tzanakakis; Apostolos Karantanas
Journal:  Sarcoma       Date:  2011-03-08

8.  Aberrations of 6q13 mapped to the COL12A1 locus in chondromyxoid fibroma.

Authors:  Taketoshi Yasuda; Jun Nishio; Janos Sumegi; Kayla M Kapels; Pamela A Althof; Jeffrey R Sawyer; John D Reith; Julia A Bridge
Journal:  Mod Pathol       Date:  2009-07-31       Impact factor: 7.842

Review 9.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

10.  Temporal Chondroblastoma with a Novel Chromosomal Translocation (2;5) (q33;q13).

Authors:  Andrew P Carlson; Howard Yonas; Garth T Olson; Kaaren K Reichard; Rafael Medina-Flores
Journal:  Skull Base Rep       Date:  2011-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.